Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Cannabidiol (CBD) has a unique therapeutic profile as it has a cannabinoid receptor-independent mechanism, limited side-effects, and patients do not seem to develop an insurmountable tolerance. Research currently focussed on the therapeutic benefits of CBD has demonstrated long-lasting neuroprotective properties against global and focal ischemic injury, such as ischemic stroke. This piece points to CBD as a major component of cannabis-based medicine as a non-psychoactive component. Further research is needed to evaluate the full clinical capabilities of CBD, including its neuroprotective effect.
Effect of citrus peel extracts on the cellular quiescence of prostate cancer cells
A recent study has revealed that citrus peel extracts (CPE) have the potential to prevent prostate cancer from recurring in post-therapy cancer patients. A component of CPE, flavonoids, have previously been found to have anticancer effects, but appear to lack the correct structure to prevent tumors in patients with prostate cancer. This specific study found that the citric acid present in CPE was the contributing factor to its anticancer effects but mentioned that flavonoids should continue to be researched for chemopreventive benefits.
A recent study has found that flavonoids isolated from Psoralea corylifolia are able to inhibit part of the insulin pathway.
Seeds of the P. corylifolia plant have been used in eastern medicine, primary in China, for years, and is now being further researched as flavonoids continue to intrigue researchers with their possible therapeutic benefits. The inhibitory activity found in this study provides evidence that flavonoids should be pursued as a potential treatment for Type-2 Diabetes.
Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
Because of the associated anti-inflammatory action, modulation of CB1R & CB2R is helpful to treat autoimmune diseases, including Multiple Sclerosis, Type-1 Diabetes Mellitus, and Rheumatoid Arthritis The full list is truly very much longer, as every illness necessarily involves the immune system and cellular communication.
The following review, written by Elaine D. Gonc ̧alves